Gastroesophageal Junction

Oncology·MeSH: Parkinson Disease 4, Autosomal Dominant Lewy Body

26 drugs in development·10 companies·3 clinical trials

Drug Pipeline by Phase

Approved(4)

Phase 3(5)

Drug	Company
bemarituzumab	FIVE PRIME THERAPEUTICS, INC. (FPRX)
Cadonilimab	Merus N.V. (MRUS)
folinic acid	Merus N.V. (MRUS)
Levoleucovorin	Merck & Co., Inc. (MRK)
zolbetuximab	Merus N.V. (MRUS)

Phase 2(5)

Drug	Company
Chemotherapeutic Agent	Merus N.V. (MRUS)
increase dose of tocilizumab	Merus N.V. (MRUS)
PF-08634404	Merus N.V. (MRUS)
sotigalimab	Apexigen, Inc. (APGN)
utidelone	BIOSTAR PHARMACEUTICALS, INC. (BSPM)

Phase 1(6)

Phase 1/Phase 2(1)

Drug	Company
Chemotherapy	Merus N.V. (MRUS)

Phase 2/Phase 3(4)

Drug	Company
CAPOX	BRISTOL MYERS SQUIBB CO (BMY)
fluoropyrimidine-	BIOSTAR PHARMACEUTICALS, INC. (BSPM)
FOLFOX	BRISTOL MYERS SQUIBB CO (BMY)
pd-1 inhibitor	BIOSTAR PHARMACEUTICALS, INC. (BSPM)

Phase 4(1)

Drug	Company
SOX chemotherapy	Merus N.V. (MRUS)

BioSniper tracks 26 drugs in development for Gastroesophageal Junction across 10 companies.

There are 3 clinical trials targeting Gastroesophageal Junction tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.